INSMED Inc (INSM)
Insmed Incorporated operates as a biopharmaceutical enterprise focused on creating and introducing medical solutions for individuals facing severe and uncommon health conditions. The company's marketed treatment, ARIKAYCE, is administered to adult patients suffering from Mycobacterium avium complex (MAC) lung disease, serving as a component of a broader antibacterial drug regimen. In its development pipeline, Insmed is advancing Brensocatib, an oral and reversible inhibitor targeting dipeptidyl peptidase 1, which is being investigated for its potential in treating bronchiectasis and other disorders mediated by neutrophils. Additionally, the firm is developing Treprostinil Palmitil Inhalation Powder, an inhaled version of the treprostinil palmitil prodrug, designed to address pulmonary arterial hypertension and various other rare lung ailments. Founded in 1988, Insmed Incorporated maintains its primary corporate offices in Bridgewater, New Jersey.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Insmed Incorporated
1-25 of 1,827 filings
Recent SEC filings with analysis
- 8-KInsmed reported Q3 2026 revenue of $524.4 million, up 268% year over year, driven by BRINSUPRI's blockbuster launch with $400.1 million in quarterly revenue,…
- 10-QInsmed's Q3 2026 revenue hit $524.4 million, up 268% year over year, driven almost entirely by the US launch of BRINSUPRI, which generated $398.1 million in…
- 8-KInsmed appointed Paul Hudson, former CEO of Sanofi and Novartis Pharmaceuticals, and Utpal Koppikar, CFO of Verily Health, as independent directors effective…
- 8-KInsmed announced CFO Sara Bonstein will step down effective October 30, 2026, after nearly seven years, staying through the October 29 Q3 earnings call.